Mid
B
BNTXAI Stock Diagnostic Report
BioNTech falls as mRNA therapy for head and neck cancer fails in mid-stage trial
BioNTech's mRNA therapy for head and neck cancer failed in a mid-stage clinical trial, causing the stock price to fall.
View Source Article ↗AI CATALYST SCORE45 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
BNTX Analysis History (Last 30 Days)